Novartis (NVS) Q1 2026 earnings review
Growth Engine Fights the Patent Cliff
Novartis is officially navigating the steepest part of its generic cliff. The loss of exclusivity for Entresto, Promacta, and Tasigna dragged total Q1 net sales down 1% YoY. More painfully, the volume loss combined with heavy R&D investments crushed profitability—Core Operating Income fell 12% and margins compressed sharply. However, the underlying growth engine is roaring. Priority brands are executing flawlessly, with Oncology surging 39% as Kisqali and Pluvicto rapidly gain market share. Management reaffirmed FY26 guidance, staying true to their narrative that 2026 will be a 'tale of two halves' where aggressive pipeline execution eventually outweighs generic erosion.
🐂 Bull Case
The 'replacement power' of Novartis's portfolio is real. Kisqali (+59%), Pluvicto (+73%), and Kesimpta (+29%) are rapidly offsetting massive generic holes. Oncology alone grew by over $1.1B YoY in absolute terms.
The successful $12B closure of the Avidity acquisition adds critical late-stage assets in neuromuscular diseases, while organic pipeline wins (Remibrutinib in CIndU, Ianalumab FDA priority review) secure the mid-term growth runway.
🐻 Bear Case
Core operating margin dropped a massive 4.8 percentage points to 37.3%. Higher R&D spending and the loss of high-margin legacy drugs are severely hurting bottom-line profitability.
Entresto sales collapsed 42% YoY. U.S. revenue declined 13% overall, proving that the generic cliff is deep and will require sustained, flawless execution from new launches just to tread water in 2026.
⚖️ Verdict: ⚪
Neutral. The pipeline and priority brands are performing exactly as management promised, but the financial realities of the Entresto patent cliff and M&A-driven margin dilution are currently suppressing earnings.
Key Themes
The Generic Cliff Takes Its Toll
Reversing. After quarters of preparing investors for the Entresto loss of exclusivity (LOE), the impact has arrived in full force. Entresto sales plummeted 42% YoY to $1.3B. Promacta (-66%) and Tasigna (-59%) compounded the pain. This generic erosion directly caused the 13% decline in U.S. regional sales and offset 13 percentage points of global volume growth.
Profitability Under Severe Pressure
Decelerating. Management called Q1 a 'strong start,' but the financial metrics contradict this optimism on the bottom line. Core operating margin fell from 42.1% in 25Q1 to 37.3% in 26Q1. The culprit is negative operating leverage: high-margin generic losses combined with a 16% USD increase in R&D investments, primarily driven by recently acquired assets like Avidity.
Net Debt Explosion
Reversing. Net debt surged from $21.9B at the end of 2025 to $38.1B by the end of 26Q1. This massive $16.2B increase was driven by the $12.0B cash acquisition of Avidity, the $6.2B annual dividend payment, and $1.9B in share buybacks. While free cash flow remains stable at $3.3B, this level of leverage reduces short-term flexibility for further major bolt-on M&A.
Oncology Franchise Surging
Accelerating. The Oncology segment is the undeniable star, growing 39% YoY to $4.0B. Kisqali (+59% to $1.5B) is capturing massive market share in early breast cancer. Pluvicto (+73% to $642M) is showing incredible momentum in the pre-taxane mCRPC setting. Scemblix (+82% to $433M) continues rapid adoption in early-line CML. This trio is the foundation of the company's mid-term growth strategy.
Neuroscience and Immunology Momentum
Stable. Kesimpta (+29% to $1.16B) continues to gain share as a high-efficacy, at-home B-cell therapy for MS. In Immunology, while Cosentyx growth was relatively flat (+2%) globally due to U.S. revenue deduction adjustments, ex-U.S. sales remain strong. Rhapsido showed robust early uptake supported by free drug programs.
Pipeline Execution & Regulatory Wins
Novartis continues to advance its 'pipeline-in-a-pill' strategy. Remibrutinib secured a positive CHMP opinion for CSU, achieved its primary endpoint in a Phase III trial for CIndU, and demonstrated superior efficacy in a Phase II food allergy study. Additionally, Ianalumab received FDA Breakthrough Therapy designation and priority review for Sjögren's disease.
U.S. Pricing and Revenue Deduction Headwinds
Macro regulatory and pricing pressures continue to manifest. Pricing had a negative 4% impact on overall net sales, including a 1% net drag from U.S. revenue deduction adjustments. Cosentyx specifically suffered a US sales decline despite demand growth due to tough YoY comparisons on these deductions, highlighting the ongoing volatility in U.S. gross-to-net pricing.
Other KPIs
Stable. Broadly in line with the $3.39 billion reported in 25Q1. Lower net income and higher tax payments were effectively offset by favorable working capital changes. This stability is critical as it supports the ongoing $10 billion share buyback program and the company's progressive dividend policy.
Accelerating. R&D spending increased 16% YoY (9% cc), significantly outpacing revenue growth. Management explicitly tied this to investments in recently acquired assets (like Avidity). This aggressive investment is a primary driver behind the current quarter's core operating margin compression.
Guidance
Reversing. After a 5% cc decline in 26Q1, guidance implies a strong acceleration in the back half of the year. This aligns with management's narrative that H1 will absorb the brunt of the Entresto generic hit, before new launches and priority brands pull full-year growth into positive territory.
Decelerating. Compared to the low-teens growth guided and achieved in FY25, profitability is taking a step back in 2026. This reflects the toxic combination of losing high-margin Entresto revenues and absorbing the 1-2% margin dilution from the Avidity integration.
Key Questions
Margin Recovery Timeline
Core operating margin fell nearly 500 basis points this quarter. With the Avidity integration underway and generic pressures peaking, what is the exact bridge and timeline to return to the 40% margin target?
Cosentyx U.S. Pricing Dynamics
U.S. sales for Cosentyx declined due to revenue deduction adjustments despite demand growth. Are these gross-to-net pressures expected to stabilize in H2, or is this a structural headwind for the remainder of 2026?
Capital Allocation Flexibility
With Net Debt jumping to $38.1B following the Avidity close, how restricted is the balance sheet regarding further bolt-on M&A over the next 12-18 months?